M. Zile
Cardiology and Cardiovascular Medicine · 2002–2019
A researcher in the Science corpus: 13 papers; trusts 3 researchers and is trusted by 7 researchers here, as inferred from the citation graph.
Subfields
- Cardiology and Cardiovascular Medicine — 101 citations into it; #124 of 906 by trust here, #67 by citations
Whom M. Zile trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts M. Zile overall
- W. Paulus
- Francis G. Spinale
- Barry A. Borlaug
- J. Forbes
- C. Tschöpe
- Sherif F. Nagueh
- M. Cooper
- B. Biondi
- Douglas L. Mann
- Véronique L. Roger
Papers from M. Zile's perspective
Ordered by how strongly the researchers M. Zile trusts endorse each paper. Same corpus, a different order for every researcher.
- Heart failure with preserved ejection fraction. (New England Journal of Medicine)
- A new look at the statistical model identification
- Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. (Journal of the American Medical Association (JAMA))
- Tissue Doppler imaging a new prognosticator for cardiovascular diseases. (Journal of the American College of Cardiology)
- Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. (European Heart Journal)
- Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) (Circulation)
- ECM remodeling in hypertensive heart disease. (Journal of Clinical Investigation)
- Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. (Journal of the American College of Cardiology)
- SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. (Journal of Clinical Investigation)
- Matricellular proteins: extracellular modulators of cell function. (Current Opinion in Cell Biology)
Their papers
- PHENOTYPE-SPECIFIC TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION: A MULTIORGAN ROADMAP (2016) — 857 citations
- Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. (2019) — 1,756 citations
- Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium. (2016) — 50 citations
- Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure (2015) — 599 citations
- Myocardial Stiffness in Patients with Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin (2015) — 620 citations
- Angiotensin-neprilysin inhibition versus enalapril in heart failure. (2014) — 6,025 citations
- Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction (2013) — 705 citations
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. (2012) — 1,037 citations
- Irbesartan in patients with heart failure and preserved ejection fraction. (2008) — 1,881 citations
- Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial (2006) — 621 citations
- Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. (2004) — 1,533 citations
- New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. (2002) — 932 citations
- New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. (2002) — 1,250 citations